Sex-Biased T-cell Exhaustion Drives Differential Immune Responses in Glioblastoma.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 09 2023
06 09 2023
Historique:
received:
08
08
2022
revised:
14
05
2023
accepted:
23
06
2023
medline:
7
9
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
ppublish
Résumé
Sex differences in glioblastoma (GBM) incidence and outcome are well recognized, and emerging evidence suggests that these extend to genetic/epigenetic and cellular differences, including immune responses. However, the mechanisms driving immunologic sex differences are not fully understood. Here, we demonstrate that T cells play a critical role in driving GBM sex differences. Male mice exhibited accelerated tumor growth, with decreased frequency and increased exhaustion of CD8+ T cells in the tumor. Furthermore, a higher frequency of progenitor exhausted T cells was found in males, with improved responsiveness to anti-PD-1 treatment. Moreover, increased T-cell exhaustion was observed in male GBM patients. Bone marrow chimera and adoptive transfer models indicated that T cell-mediated tumor control was predominantly regulated in a cell-intrinsic manner, partially mediated by the X chromosome inactivation escape gene Kdm6a. These findings demonstrate that sex-biased predetermined behavior of T cells is critical for inducing sex differences in GBM progression and immunotherapy response. Immunotherapies in patients with GBM have been unsuccessful due to a variety of factors, including the highly immunosuppressive tumor microenvironment in GBM. This study demonstrates that sex-biased T-cell behaviors are predominantly intrinsically regulated, further suggesting sex-specific approaches can be leveraged to potentially improve the therapeutic efficacy of immunotherapy in GBM. See related commentary by Alspach, p. 1966. This article is featured in Selected Articles from This Issue, p. 1949.
Identifiants
pubmed: 37378557
pii: 727537
doi: 10.1158/2159-8290.CD-22-0869
pmc: PMC10481130
mid: NIHMS1914155
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2090-2105Subventions
Organisme : NCI NIH HHS
ID : F30 CA250254
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA245705
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS105068
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS127083
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2023 The Authors; Published by the American Association for Cancer Research.
Références
Neurooncol Adv. 2022 May 27;4(1):vdac082
pubmed: 35821678
Cell Prolif. 2022 Oct;55(10):e13295
pubmed: 35860850
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
ESMO Open. 2021 Oct;6(5):100251
pubmed: 34455288
JAMA Oncol. 2020 Jul 1;6(7):1003-1010
pubmed: 32437507
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
Brain. 2020 Dec 1;143(12):3629-3652
pubmed: 33253355
Immunity. 2022 Jul 12;55(7):1268-1283.e9
pubmed: 35700739
JCI Insight. 2017 Jul 20;2(14):
pubmed: 28724802
Neuro Oncol. 2018 Mar 27;20(4):576-577
pubmed: 29474647
Biol Sex Differ. 2020 Apr 15;11(1):17
pubmed: 32295632
Oncoimmunology. 2018 Sep 5;7(12):e1501137
pubmed: 30524896
Nature. 2022 Jun;606(7915):791-796
pubmed: 35322234
Cancer Discov. 2022 Jan;12(1):154-171
pubmed: 34610950
Pharmacol Ther. 2005 Dec;108(3):308-19
pubmed: 15951022
Clin Cancer Res. 2018 Sep 1;24(17):4175-4186
pubmed: 29437767
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
J Neuroinflammation. 2021 Mar 12;18(1):70
pubmed: 33712031
J Clin Oncol. 2022 May 1;40(13):1474-1486
pubmed: 35119908
Front Immunol. 2021 Jul 20;12:715234
pubmed: 34354714
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
J Neurooncol. 2021 Jan;151(1):41-53
pubmed: 32253714
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Sci Transl Med. 2019 Jan 2;11(473):
pubmed: 30602536
Nature. 2012 Aug 16;488(7411):404-8
pubmed: 22842901
JCI Insight. 2017 Aug 3;2(15):
pubmed: 28768910
Nat Immunol. 2023 May;24(5):780-791
pubmed: 36928413
Nat Immunol. 2022 Jun;23(6):848-860
pubmed: 35624210
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
JAMA Oncol. 2019 Apr 01;5(4):529-536
pubmed: 30605213
Sci Immunol. 2022 Jul;7(73):eabq2630
pubmed: 35420889
J Virol. 2003 Apr;77(8):4911-27
pubmed: 12663797
Neurooncol Adv. 2022 Feb 26;4(1):vdac025
pubmed: 35402913
Sci Rep. 2018 May 9;8(1):7352
pubmed: 29743610
Nat Rev Immunol. 2010 Aug;10(8):594-604
pubmed: 20651746
Nat Rev Cancer. 2021 Jun;21(6):393-407
pubmed: 33879867
Nat Commun. 2022 Feb 17;13(1):925
pubmed: 35177622
Cancer Discov. 2020 Aug;10(8):1210-1225
pubmed: 32300059
Clin Cancer Res. 2021 Aug 1;27(15):4311-4324
pubmed: 34016641
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Nat Med. 2018 Sep;24(9):1459-1468
pubmed: 30104766
Nucleic Acids Res. 2010 Jan;38(Database issue):D792-9
pubmed: 19906719
Elife. 2017 Dec 18;6:
pubmed: 29251591
PLoS Pathog. 2020 Jun 24;16(6):e1008555
pubmed: 32579593
J Natl Cancer Inst. 2019 Aug 1;111(8):772-781
pubmed: 31106827